share_log

中國生物製藥：二零二四年中期報告

SINO BIOPHARM: 2024 INTERIM REPORT

HKEX ·  Sep 26, 2024 16:30

Summary by Moomoo AI

中國生物製藥有限公司（「本公司」）公佈截至2024年6月30日止六個月的未經審核中期業績。期內，本公司收入達人民幣158.7億元，同比增長11.1%；歸屬於母公司持有者的盈利為人民幣30.2億元，同比大幅增加139.7%。基於歸屬於母公司持有者之經調整非《香港財務報告準則》歸母淨利潤計算之每股基本盈利為人民幣8.34分，同比增長15.0%。本公司董事會宣佈派發截至2024年6月30日止六個月之中期股息每股3港仙。本公司於開曼群島註冊成立，主要業務包括生產、銷售及配銷中藥現代製劑及西藥產品。本公司股份於香港聯合交易所有限公司主板上市。
中國生物製藥有限公司（「本公司」）公佈截至2024年6月30日止六個月的未經審核中期業績。期內，本公司收入達人民幣158.7億元，同比增長11.1%；歸屬於母公司持有者的盈利為人民幣30.2億元，同比大幅增加139.7%。基於歸屬於母公司持有者之經調整非《香港財務報告準則》歸母淨利潤計算之每股基本盈利為人民幣8.34分，同比增長15.0%。本公司董事會宣佈派發截至2024年6月30日止六個月之中期股息每股3港仙。本公司於開曼群島註冊成立，主要業務包括生產、銷售及配銷中藥現代製劑及西藥產品。本公司股份於香港聯合交易所有限公司主板上市。
Sino Biopharm Limited ("the Company") announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 15.87 billion, an 11.1% year-on-year increase; the profit attributable to owners of the parent company was RMB 3.02 billion, a significant 139.7% year-on-year increase. The adjusted basic earnings per share attributable to owners of the parent company, calculated based on non-Hong Kong Financial Reporting Standards, was RMB 8.34, a 15.0% year-on-year increase. The Board of Directors of the Company declared an interim dividend of 3 Hong Kong cents per share for the six months ended June 30, 2024. The Company is incorporated in the Cayman Islands, with main businesses including manufacturing, selling, and distributing modern traditional Chinese medicine formulations and Western medicine products. The Company's shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited.
Sino Biopharm Limited ("the Company") announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 15.87 billion, an 11.1% year-on-year increase; the profit attributable to owners of the parent company was RMB 3.02 billion, a significant 139.7% year-on-year increase. The adjusted basic earnings per share attributable to owners of the parent company, calculated based on non-Hong Kong Financial Reporting Standards, was RMB 8.34, a 15.0% year-on-year increase. The Board of Directors of the Company declared an interim dividend of 3 Hong Kong cents per share for the six months ended June 30, 2024. The Company is incorporated in the Cayman Islands, with main businesses including manufacturing, selling, and distributing modern traditional Chinese medicine formulations and Western medicine products. The Company's shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    JIUYUAN GENE
    02566
    -- 7.140
    LEE'S PHARM
    00950
    -- 1.350
    PURAPHARM
    01498
    -- 0.570
    NEP INTERLONG
    08329
    -- 0.160
    KINTOR PHARMA-B
    09939
    -- 1.020
    Log In for the Full List
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
    Discussing
    Tesla's earnings caused fluctuations, what's your market outlook？
    Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
    TSLA earnings preview: Grab rewards by guessing the opening price!